Tempus AI (NASDAQ:TEM) Trading Down 5.3% – Time to Sell?

Shares of Tempus AI, Inc. (NASDAQ:TEM) dropped 5.3% during mid-day trading on Thursday . The stock traded as low as $42.71 and last traded at $43.09. Approximately 4,113,447 shares were traded during trading, a decline of 16% from the average daily volume of 4,873,981 shares. The stock had previously closed at $45.50.

Analyst Upgrades and Downgrades

TEM has been the topic of several recent analyst reports. Morgan Stanley increased their target price on shares of Tempus AI from $50.00 to $60.00 and gave the stock an “overweight” rating in a research note on Thursday, March 6th. Piper Sandler cut their price objective on shares of Tempus AI from $70.00 to $55.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Guggenheim restated a “buy” rating on shares of Tempus AI in a report on Tuesday, February 25th. JPMorgan Chase & Co. downgraded shares of Tempus AI from an “overweight” rating to a “neutral” rating and raised their price target for the stock from $50.00 to $55.00 in a report on Tuesday, February 25th. Finally, Wolfe Research cut shares of Tempus AI from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 26th. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $61.18.

Tempus AI Price Performance

The company’s 50-day moving average price is $55.15 and its 200-day moving average price is $51.92. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69.

Insider Transactions at Tempus AI

In other news, EVP Andrew Polovin sold 1,130 shares of Tempus AI stock in a transaction on Monday, December 16th. The shares were sold at an average price of $40.23, for a total transaction of $45,459.90. Following the completion of the sale, the executive vice president now directly owns 244,955 shares of the company’s stock, valued at approximately $9,854,539.65. The trade was a 0.46 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Eric P. Lefkofsky sold 3,240,234 shares of Tempus AI stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $58.75, for a total transaction of $190,363,747.50. Following the sale, the chief executive officer now owns 4,895,589 shares in the company, valued at $287,615,853.75. This represents a 39.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 5,755,906 shares of company stock valued at $322,788,693.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Operose Advisors LLC acquired a new position in shares of Tempus AI during the fourth quarter worth about $25,000. First Horizon Advisors Inc. purchased a new position in Tempus AI during the third quarter worth about $30,000. Farther Finance Advisors LLC purchased a new position in Tempus AI during the fourth quarter worth about $34,000. Prestige Wealth Management Group LLC raised its holdings in Tempus AI by 910.4% during the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock worth $36,000 after purchasing an additional 965 shares in the last quarter. Finally, NewEdge Advisors LLC purchased a new position in Tempus AI during the fourth quarter worth about $49,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.